From Financial Modeling Prep: 2025-03-21 07:00:00

OptiNose, Inc. (NASDAQ:OPTN) faces a pessimistic outlook as investment analysts set a target price significantly lower than its current market price, reflecting concerns about the company’s stock performance.

Collegium Pharmaceutical, Inc. (COLL) is deemed overvalued by 41.93% despite a positive EPS of $1.86 and a PE ratio of 13.36, leading to cautious investor sentiment towards the company.

Alkermes plc (ALKS) appears slightly undervalued with an EPS of $2.20 and a PE ratio of 12.96, indicating high growth potential compared to its peers in the pharmaceutical industry.

Deciphera Pharmaceuticals, Inc. (DCPH) shows an overvaluation of 32.74% with a negative EPS of -$2.21 and a negative PE ratio of -7.04, raising concerns among investors despite its market cap of $2.21 billion.



Read more at Financial Modeling Prep:: Comparative Analysis of Pharmaceutical Companies: …